Profile data is unavailable for this security.
About the company
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
- Revenue in CHF (TTM)0.00
- Net income in CHF-19.62m
- Incorporated1996
- Employees50.00
- LocationSpexis AGHegenheimermattweg 125ALLSCHWIL 4123SwitzerlandCHE
- Phone+41 615671600
- Fax+41 615671601
- Websitehttps://spexisbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tian'an Pharmaceutical Co Ltd | 9.05m | 2.67m | 3.60m | -- | 0.0236 | 0.0051 | 1.16 | 0.3981 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Jupiter Bioscience Ltd | -1.02bn | -1.02bn | 3.76m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.42 | -- | 5.61 | -- | 61.37 | -- | 17.32 | -- | -- | -- | 10.48 | 42.43 | 29.30 | 20.92 | 22.82 | 55.40 | -16.74 |
| Processa Pharmaceuticals Inc | 0.00 | -8.69m | 3.77m | 13.00 | -- | 0.6477 | -- | -- | -5.36 | -5.36 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -115.58 | -84.35 | -133.48 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0016 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| Spexis AG | 0.00 | -19.62m | 3.86m | 50.00 | -- | -- | -- | -- | -0.3597 | -0.3597 | 0.00 | -0.0546 | 0.00 | -- | -- | 0.00 | -84.79 | -53.28 | -149.58 | -68.93 | -- | -- | -- | -1,117.43 | -- | -- | 1.69 | -- | -- | -- | -5.75 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -9.65m | 3.89m | 2.00 | -- | 0.8317 | -- | -- | -7.72 | -7.72 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -82.84 | -205.36 | -120.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Rua Bioscience Ltd | 45.52k | -7.27m | 3.90m | -- | -- | 1.09 | -- | 85.61 | -0.087 | -0.087 | 0.0005 | 0.0424 | 0.006 | 1.40 | 0.1507 | -- | -95.63 | -32.16 | -101.42 | -34.82 | -137.81 | -- | -15,981.77 | -7,599.16 | 2.91 | -- | 0.0214 | -- | -76.00 | -- | -130.21 | -- | -69.46 | -- |
| Genxone SA | 361.83k | -837.54k | 3.93m | 19.00 | -- | 1.33 | -- | 10.85 | -1.14 | -1.14 | 0.4938 | 4.02 | 0.1031 | 11.74 | 2.49 | -- | -23.87 | 14.58 | -24.84 | 16.46 | -39.53 | 48.42 | -231.47 | 20.41 | 16.71 | -- | 0.0028 | -- | -77.38 | 111.39 | -874.87 | -- | -28.78 | -- |
| Silo Pharma Inc | 61.31k | -2.93m | 3.96m | 3.00 | -- | 0.6495 | -- | 64.67 | -1.16 | -1.18 | 0.0242 | 1.60 | 0.0079 | -- | -- | 24,040.00 | -37.69 | -24.90 | -43.50 | -26.39 | 91.90 | 82.79 | -4,777.02 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
| Valeo Pharma Inc | 33.44m | -20.12m | 4.02m | 70.00 | -- | -- | -- | 0.1202 | -0.3412 | -0.3412 | 0.5669 | -0.6388 | 1.37 | 5.00 | 11.08 | 427,016.00 | -82.64 | -64.35 | -- | -113.22 | 16.51 | 23.88 | -60.18 | -69.71 | 0.202 | -1.16 | 9.94 | -- | 94.31 | 65.20 | -8.01 | -- | 76.61 | -- |
| CRISM' Therapeutics Corp | 0.00 | -2.03m | 4.06m | 4.00 | -- | 0.3085 | -- | -- | -0.2063 | -0.8326 | 0.00 | 0.3556 | 0.00 | -- | -- | 0.00 | -14.26 | -8.67 | -14.89 | -9.02 | -- | -- | -- | -- | -- | -3.51 | 0.00 | -- | -- | -- | 8.21 | -- | -- | -- |
| Sanai Health Industry Group Co Ltd | 11.74m | 1.57m | 4.09m | 156.00 | 2.75 | 0.1044 | 3.55 | 0.3482 | 0.0891 | 0.0891 | 0.7403 | 2.35 | 0.2261 | 13.97 | 5.76 | 1,581,951.00 | 1.74 | 2.31 | 2.21 | 3.65 | 17.99 | 34.87 | 7.71 | 6.56 | 4.10 | -3.68 | 0.1077 | 0.00 | -30.60 | 16.04 | -36.23 | -- | -75.21 | -- |
| Stemtech Corp | 4.56m | -4.34m | 4.11m | 45.00 | -- | -- | -- | 0.8998 | -0.0518 | -0.0518 | 0.0529 | -0.0359 | 1.33 | 8.39 | 42.31 | -- | -126.26 | -- | -- | -- | 77.87 | -- | -95.16 | -- | 0.065 | -2.59 | -- | -- | 7.94 | -- | 36.45 | -- | -- | -- |
| CYANOTECH CORP | 20.25m | -4.34m | 4.14m | 77.00 | -- | 0.4563 | -- | 0.2045 | -0.7549 | -0.7549 | 3.56 | 1.53 | 0.8895 | 2.05 | 12.12 | 309,389.60 | -19.04 | -3.46 | -29.60 | -4.46 | 24.72 | 34.54 | -21.41 | -3.58 | 0.3354 | -6.61 | 0.377 | -- | -0.4616 | -5.24 | -53.11 | -- | -6.42 | -- |
Data as of Jul 31 2024. Currency figures normalised to Spexis AG's reporting currency: Swiss Franc CHF
1.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 29 Aug 2024 | 526.32k | 0.78% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Jul 2024 | 77.22k | 0.11% |
| Credit Suisse AGas of 31 Jul 2024 | 25.45k | 0.04% |
| BlackRock Asset Management Schweiz AGas of 05 Sep 2024 | 18.25k | 0.03% |
| Pictet Asset Management SAas of 31 May 2024 | 17.82k | 0.03% |
| Banque Cantonale Vaudoise (Investment Management)as of 31 Mar 2024 | 6.00k | 0.01% |
| LLB Asset Management AGas of 30 Jun 2024 | 2.35k | 0.00% |
| BlackRock Advisors (UK) Ltd.as of 31 Jul 2023 | 1.56k | 0.00% |
| Carne Global Fund Managers (Schweiz) AGas of 31 Jul 2024 | 1.50k | 0.00% |
More ▼
Data from 30 Jun 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
